The U.S. Supreme Court has been asked to urgently intervene in a legal battle over access to abortion medication, after a lower court ruling moved to restrict how the drug can be distributed nationwide.
Danco Laboratories, a manufacturer of the abortion pill mifepristone, filed an emergency appeal seeking to pause a decision by the Fifth Circuit U.S. Court of Appeals that requires the drug to be dispensed only in person. The ruling effectively blocks access to the medication through telehealth services and mail delivery.
The appeals court decision came at the request of the state of Louisiana and marks a significant shift in abortion access policy. Since the overturning of Roe v. Wade in 2022, telehealth and mail distribution of abortion pills have become critical options for patients, particularly in states with strict abortion bans.
In its filing, Danco argued that the lower court’s ruling disrupts long-standing guidelines set by the Food and Drug Administration, which had allowed remote access to mifepristone since pandemic-era policy changes were made permanent in 2023. The company warned that enforcing in-person dispensing nationwide could create confusion, limit access to care, and threaten its business operations, as the drug is its sole product.
Reproductive rights advocates have also voiced strong opposition. Planned Parenthood Action Fund criticized the ruling, arguing that it undermines access to safe and effective healthcare and places additional burdens on patients seeking abortion services.
Medication abortions now account for more than half of all abortions in the United States, making the outcome of this case highly consequential. The Supreme Court had previously declined to restrict access to mifepristone in a separate case, ruling that challengers lacked legal standing.
Legal experts say the current dispute raises broader questions about whether a single state can influence nationwide access to federally approved medications, as well as the limits of judicial authority over public health policy.
The Supreme Court’s decision on whether to pause the ruling could have immediate and far-reaching implications for abortion access, healthcare delivery, and regulatory authority across the country.